XML 49 R21.htm IDEA: XBRL DOCUMENT v3.2.0.727

Collaborative Research and Development Agreements (Tables)

6 Months Ended

Jun. 30, 2015

Astra Zeneca

Summary of Revenue Recognized under Various Agreements

The following table summarizes the revenues earned under our agreement with AstraZeneca, included as collaboration revenue in our consolidated statements of operations (in thousands):

	Three Months Ended								Six Months Ended
	June 30,								June 30,
	2015				2014				2015				2014
Initial payment	$	63			$	180			$	126			$	360
Subsequent payment		237				675				474				1,350
Performance of research activities		630				545				801				1,432
Total	$	930			$	1,400			$	1,401			$	3,142

National Institutes of Health

Summary of Revenue Recognized under Various Agreements

The following table summarizes the revenues recognized under the various arrangements with the NIH and NIAID (in thousands):

	Three Months Ended								Six Months Ended
	June 30,								June 30,
	2015				2014				2015				2014
NIAID contracts	$	-			$	965			$	-			$	1,839
All other NIH contracts		101				42				249				293
Total grant revenue	$	101			$	1,007			$	249			$	2,132

X

- Definition

Tabular disclosure of the recognition of revenue arrangements under which the entity does or will perform multiple revenue-generating activities, categorized by type of arrangement. This item includes certain revenue arrangements that include software elements. This item does not include multiple-deliverable arrangements for industries that prepare disclosures under specific requirements (for instance, construction-type and production-type contracts) otherwise provided for in the taxonomy.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef



-Publisher FASB



-Name Accounting Standards Codification



-Topic 605



-SubTopic 25



-Section 50



-Paragraph 1



-URI http://asc.fasb.org/extlink&oid=51671369&loc=d3e50766-111635



Reference 2: http://www.xbrl.org/2003/role/presentationRef



-Publisher FASB



-Name Accounting Standards Codification



-Topic 605



-SubTopic 25



-Section 50



-Paragraph 2



-URI http://asc.fasb.org/extlink&oid=51671369&loc=SL6750900-111635

+ Details

Name:	us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Details

Name:	us-gaap_CounterpartyNameAxis=dvax_AstraZenecaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_CounterpartyNameAxis=dvax_NationalInstitutesOfHealthMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: